AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17884837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral support intervention (telephone counseling sessions with newsletters)
Number of subjects: 53
Study 17884837 — intervention group
Group type: COMPARATOR
Intervention: Control condition (quarterly mailings)
Number of subjects: 53
Study 15669885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 to 150 mg/day
Number of subjects: 60
Study 15669885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12668540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received confidential profiles of benzodiazepine prescription use and educational bulletins for 6 months.
Number of subjects: 1624
Study 12668540 — intervention group
Group type: COMPARATOR
Intervention: Control group received feedback and educational bulletins about first-line antihypertension drug prescribing.
Number of subjects: 1624
Study 10606284 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 10606284 — intervention group
Group type: COMPARATOR
Intervention: No androgen deprivation
Number of subjects: 0
Study 7851595 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict morphology analysis 1 month before the beginning of IUI following the criteria of Kruger et al.
Number of subjects: 74
Study 7851595 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict morphology analysis with morphology index > 10%
Number of subjects: 74
Study 7851595 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict morphology analysis in pure male infertility group
Number of subjects: 74
Study 1780738 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (7 micrograms/kg b.w./min)
Number of subjects: 19
Study 1780738 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-Dopamine (7 IU/kg + dopamine)
Number of subjects: 19
Study 6780974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol irrigation (group II, n = 12)
Number of subjects: 28
Study 6780974 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigated (group I, n = 16)
Number of subjects: 28
Study 31488371 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1371
Study 31488371 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic repolarisation dynamics of 7.5 deg or higher
Number of subjects: 1371
Study 31488371 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic repolarisation dynamics less than 7.5 deg
Number of subjects: 1371
Study 31488371 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 1371
Study 28834830 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation using absorbable mesh plates and screws
Number of subjects: 55
Study 28834830 — intervention group
Group type: COMPARATOR
Intervention: Orbital floor reconstruction
Number of subjects: 55
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of covariates in randomization
Number of subjects: 300
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of covariates
Number of subjects: 300
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Significance tests of baseline balance
Number of subjects: 300
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for baseline measures of primary outcome
Number of subjects: 300
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis adjusting for all covariates
Number of subjects: 300
Study 25648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis of primary outcome
Number of subjects: 300
Study 24261335 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal, social, and environmental factors influencing physical activity
Number of subjects: 2415
Study 21380992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 20
Study 21380992 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation without LRM
Number of subjects: 20
Study 19736895 — intervention group
Group type: EXPERIMENTAL
Intervention: The needle catcher surgical instrument
Number of subjects: 20
Study 17413099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein (HP) group; 1.2 g protein . kg(‐1) . d(‐1)
Number of subjects: 36
Study 17413099 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein (LP) group; 0.9 g protein . kg(‐1) . d(‐1)
Number of subjects: 36
Study 17413099 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 36
Study 15492337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice daily
Number of subjects: 196
Study 15492337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin, 0.4 mg once daily
Number of subjects: 196
Study 15492337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin and tamsulosin
Number of subjects: 196
Study 15492337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 11444447 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 2% lidocaine (0.08 mL.cm(‐1)) followed by iv normal saline and then propofol
Number of subjects: 120
Study 11444447 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural normal saline followed by iv 2% lidocaine (0.05 mL.kg(‐1)) then propofol
Number of subjects: 120
Study 11444447 — intervention group
Group type: COMPARATOR
Intervention: Epidural normal saline followed by iv normal saline then iv propofol
Number of subjects: 120
Study 10195235 — intervention group
Group type: EXPERIMENTAL
Intervention: REMUNE (gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant)
Number of subjects: 0
Study 7641247 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 16
Study 7641247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2666452 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac 200 mg twice daily
Number of subjects: 17
Study 2666452 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 17
Study 2666452 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 359251 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily (increased by 250 mg daily for some patients)
Number of subjects: 20
Study 359251 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily (increased by 250 mg daily for some patients)
Number of subjects: 20
Study 30614013 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL-rhEGF
Number of subjects: 24
Study 30614013 — intervention group
Group type: COMPARATOR
Intervention: AFXL-Aloe
Number of subjects: 24
Study 29785496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bareback sexually explicit media (SEM) consumption
Number of subjects: 659
Study 29785496 — intervention group
Group type: COMPARATOR
Intervention: PrEP disclosure
Number of subjects: 659
Study 29785496 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived partner attractiveness
Number of subjects: 659
Study 28771627 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 days)
Number of subjects: 300
Study 28771627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24424433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (70 participants)
Number of subjects: 110
Study 24424433 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (40 participants)
Number of subjects: 110
Study 23275453 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (n=16)
Number of subjects: 31
Study 23275453 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy milk (n=15)
Number of subjects: 31
Study 19778663 — intervention group
Group type: EXPERIMENTAL
Intervention: PON-1 glutamine isotype at codon 192
Number of subjects: 793
Study 19778663 — intervention group
Group type: EXPERIMENTAL
Intervention: PON-1 methionine isotype at codon 55
Number of subjects: 793
Study 19778663 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 793
Study 17297383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifalazil 25 mg
Number of subjects: 170
Study 17297383 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 1.0 g
Number of subjects: 170
Study 15385119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/m2 daily for 5 days every 3 weeks (Arm A)
Number of subjects: 57
Study 15385119 — intervention group
Group type: COMPARATOR
Intervention: 2.1 mg/m2 weekly for 3 weeks out of 4 (Arm B)
Number of subjects: 57
Study 11256875 — intervention group
Group type: EXPERIMENTAL
Intervention: Education class on osteoporosis
Number of subjects: 508
Study 11256875 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus BMD testing
Number of subjects: 508
Study 11256875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 508
Study 9789709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucinators (n = 14)
Number of subjects: 35
Study 9789709 — intervention group
Group type: COMPARATOR
Intervention: Non-hallucinating controls (n = 21)
Number of subjects: 35
Study 9789709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthony D‐15 (LD) test
Number of subjects: 35
Study 9789709 — intervention group
Group type: EXPERIMENTAL
Intervention: Vis tech tables (VT) at 1.5 cycles per degree
Number of subjects: 35
Study 9789709 — intervention group
Group type: EXPERIMENTAL
Intervention: Vis tech tables (VT) at 3 cycles per degree
Number of subjects: 35
Study 9789709 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular Pelli‐Robson test (PR)
Number of subjects: 35
Study 8005182 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg tds)
Number of subjects: 10
Study 8005182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg tds)
Number of subjects: 10
Study 8005182 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (10 mg)
Number of subjects: 10
Study 8005182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8005182 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (250 mg tds)
Number of subjects: 10
Study 2810238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 24
Study 2810238 — intervention group
Group type: COMPARATOR
Intervention: Dilation and massage
Number of subjects: 24
Study 2810238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery (after crossover)
Number of subjects: 24
Study 2810238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery (select group)
Number of subjects: 24
Study 2810238 — intervention group
Group type: COMPARATOR
Intervention: Dilation and massage (select group)
Number of subjects: 24
Study 31863406 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus migraine education (ACT-ED)
Number of subjects: 136
Study 31863406 — intervention group
Group type: COMPARATOR
Intervention: Support plus migraine education (S-ED)
Number of subjects: 136
Study 30858518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (n = 18)
Number of subjects: 34
Study 30858518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 34
Study 29092982 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of 20 mg/kg IV TXA before incision (group A)
Number of subjects: 150
Study 29092982 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus followed by a second bolus of 1 g IV TXA three hours later (group B)
Number of subjects: 150
Study 29092982 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus followed by two boluses of 1 g IV TXA three and six hours later (group C)
Number of subjects: 150
Study 29092982 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 150
Study 29092982 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 150
Study 25096409 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SET)
Number of subjects: 41
Study 25096409 — intervention group
Group type: COMPARATOR
Intervention: Direct communication (non-story)
Number of subjects: 41
Study 25096409 — intervention group
Group type: COMPARATOR
Intervention: Non-story communication
Number of subjects: 41
Study 25096409 — intervention group
Group type: COMPARATOR
Intervention: Story communication
Number of subjects: 41
Study 23200803 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncardioselective β blockers
Number of subjects: 2670
Study 23200803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective β blockers
Number of subjects: 2670
Study 21331773 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL
Number of subjects: 131
Study 21331773 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCNL
Number of subjects: 131
Study 18381090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologist/Oncologist involvement in diagnosis and management
Number of subjects: 0
Study 18381090 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for clinical trials and drug development
Number of subjects: 0
Study 16434531 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate (OCA)
Number of subjects: 187
Study 16434531 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staples
Number of subjects: 187
Study 16434531 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture (monocryl)
Number of subjects: 187
Study 12761013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (4 mg)
Number of subjects: 240
Study 12761013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 240
Study 12761013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 240
Study 12761013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mL normal saline)
Number of subjects: 240
Study 11061604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-etoposide-based chemotherapy
Number of subjects: 332
Study 9052565 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SUPEX) for 12 weeks
Number of subjects: 55
Study 9052565 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (HOMEX) for 12 weeks
Number of subjects: 55
Study 9052565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SUPEX and HOMEX)
Number of subjects: 55
Study 7913674 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data with autocorrelation structure
Number of subjects: 2
Study 7913674 — intervention group
Group type: EXPERIMENTAL
Intervention: Different values of the correlation parameters, gamma and theta
Number of subjects: 2
Study 3292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-Cut needle
Number of subjects: 1192
Study 31879194 — intervention group
Group type: EXPERIMENTAL
Intervention: Microelectrodes coupled to a 4 MHz generator in cutting mode
Number of subjects: 22
Study 31879194 — intervention group
Group type: COMPARATOR
Intervention: Microelectrodes coupled to a 4 MHz generator in coagulation mode
Number of subjects: 22
Study 31300951 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric sealant (Group S)
Number of subjects: 81
Study 31300951 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 81
Study 31219248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (5 mg/50 mg)
Number of subjects: 19
Study 31219248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (5 mg/100 mg)
Number of subjects: 19
Study 31219248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (15 mg/50 mg)
Number of subjects: 19
Study 31219248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (15 mg/100 mg)
Number of subjects: 19
Study 28543263 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g mesalazine once daily (SAG-37)
Number of subjects: 675
Study 28543263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAG-37)
Number of subjects: 675
Study 28543263 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g mesalazine once daily (SAG-51)
Number of subjects: 675
Study 28543263 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g mesalazine once daily (SAG-51)
Number of subjects: 675
Study 28543263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAG-51)
Number of subjects: 675
Study 25873097 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session medical education program on structured hypertension management for general practitioners.
Number of subjects: 24
Study 25873097 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 24
Study 23218998 — intervention group
Group type: COMPARATOR
Intervention: 7 hours of sleep (reference group)
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration with prevalent sleep apnea
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration with prevalent sleep apnea
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration without sleep apnea
Number of subjects: 18755
Study 23218998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration without sleep apnea
Number of subjects: 18755
Study 21114549 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/kg karaya saponin
Number of subjects: 80
Study 21114549 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg karaya saponin
Number of subjects: 80
Study 21114549 — intervention group
Group type: EXPERIMENTAL
Intervention: karaya saponin (various doses)
Number of subjects: 80
Study 18165565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 90
Study 18165565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.75 mg/kg
Number of subjects: 90
Study 18165565 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 25 mg
Number of subjects: 90
Study 16488054 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1
Number of subjects: 83
Study 16488054 — intervention group
Group type: COMPARATOR
Intervention: Etoposide 100 mg/m2 on days 1-3 plus cisplatin 75 mg/m2 on day 1
Number of subjects: 83
Study 16488054 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 83
Study 16488054 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 83
Study 14673011 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (0.5 mg/kg, i.v.)
Number of subjects: 25
Study 14673011 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 11036120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein‐associated phospholipase A2
Number of subjects: 580
Study 11036120 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐reactive protein
Number of subjects: 580
Study 11036120 — intervention group
Group type: EXPERIMENTAL
Intervention: White‐cell count
Number of subjects: 580
Study 11036120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 580
Study 11036120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coronary event)
Number of subjects: 580
Study 9377844 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 18
Study 8412414 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg d-fenfluramine
Number of subjects: 18
Study 8412414 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg d-fenfluramine
Number of subjects: 18
Study 8412414 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg l-fenfluramine
Number of subjects: 18
Study 8412414 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chlorpromazine
Number of subjects: 18
Study 8412414 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 18
Study 8412414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3321394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 21
Study 3321394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29476933 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Continuum (CEC) program for 16 weeks
Number of subjects: 28
Study 26756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 124
Study 26756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 124
Study 26756518 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 124
Study 26756518 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 124
Study 25646929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 600 mcg
Number of subjects: 84
Study 25646929 — intervention group
Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 84
Study 23298079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel injection
Number of subjects: 21
Study 23298079 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated treatment planning using predicted doses from OVH
Number of subjects: 21
Study 23298079 — intervention group
Group type: COMPARATOR
Intervention: Manual treatment planning (control)
Number of subjects: 21
Study 20205482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (SGLT2 inhibitor)
Number of subjects: 0
Study 18155037 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention
Number of subjects: 96
Study 18155037 — intervention group
Group type: COMPARATOR
Intervention: Usual care for orphans
Number of subjects: 96
Study 15889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised and home-based impact exercise training
Number of subjects: 160
Study 15889312 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 160